Enovis Corp
$ 27.96
-4.51%
04 Dec - close price
- Market Cap 1,674,505,000 USD
- Current Price $ 27.96
- High / Low $ 29.26 / 27.84
- Stock P/E N/A
- Book Value 35.33
- EPS -24.36
- Next Earning Report 2026-02-19
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.01 %
- ROE -0.51 %
- 52 Week High 49.38
- 52 Week Low 25.47
About
Enovis Corporation is a prominent global leader in the medical technology landscape, headquartered in Wilmington, Delaware, specializing in innovative orthopedic and rehabilitation solutions that significantly improve patient care and outcomes. The company's unwavering commitment to research and development empowers it to deliver high-quality medical devices and therapies tailored to the evolving needs of healthcare providers and patients. With a strategic focus on sustainability and corporate social responsibility, Enovis is well-positioned for growth in the dynamic healthcare sector, bolstered by a robust intellectual property portfolio and strategic partnerships that enhance its capability to drive advancements in care delivery and maintain its competitive edge.
Analyst Target Price
$48.11
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-06 | 2025-08-07 | 2025-04-30 | 2025-02-20 | 2024-11-06 | 2024-08-07 | 2024-05-02 | 2024-02-22 | 2023-11-07 | 2023-08-03 | 2023-05-04 | 2023-02-23 |
| Reported EPS | 0.75 | -0.64 | 0.81 | 0.98 | 0.73 | 0.62 | 0.5 | 0.79 | 0.56 | 0.61 | 0.44 | 0.72 |
| Estimated EPS | 0.65 | 0.7187 | 0.7438 | 0.9157 | 0.62 | 0.59 | 0.48 | 0.74 | 0.54 | 0.52 | 0.37 | 0.66 |
| Surprise | 0.1 | -1.3587 | 0.0662 | 0.0643 | 0.11 | 0.03 | 0.02 | 0.05 | 0.02 | 0.09 | 0.07 | 0.06 |
| Surprise Percentage | 15.3846% | -189.0497% | 8.9002% | 7.022% | 17.7419% | 5.0847% | 4.1667% | 6.7568% | 3.7037% | 17.3077% | 18.9189% | 9.0909% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-02-19 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | 0.8592 |
| Currency | USD |
Previous Dividend Records
| Jan 1970 | |
|---|---|
| Payment Date | None |
| Amount | $0.0 |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: ENOV
2025-11-02 11:10:37
This article provides a comprehensive overview of Enovis Corporation (ENOV) stock performance, key financial metrics, and company information. It details price changes, market capitalization, earnings reports, employee figures, and analyst ratings, alongside recent insider transactions and ETF holdings. The article also includes frequently asked questions about ENOV stock.
2025-10-17 00:50:23
This Yahoo Finance page provides a brief overview of Enovis Corporation (ENOV), a medical technology company. It highlights that Argus issued a report on ENOV on October 8, 2025, noting the company's sector as Healthcare, a current price of $31.19, and encourages users to upgrade for full access to premium research reports and detailed company profiles.
2025-10-14 19:40:58
Enovis Corp., a small-cap industrial manufacturer, is facing a revision in its stock evaluation due to mixed market signals and significant challenges over the past year, including a -26.08% return contrasting with the S&P 500's gain. Technical indicators show a cautious outlook with mixed bullish and bearish signals across different timeframes and indicators. The company's year-to-date return of -32.25% further highlights its struggles against the market.
2025-10-14 17:06:00
Enovis Corporation (ENOV) stock rose 3.3% after announcing the sale of its Dr. Comfort diabetic shoe business to Promus Equity Partners for up to $60 million. This strategic divestiture aims to focus the company on its core Prevention & Recovery business segment. Despite the positive news, Enovis shares have been volatile and are down almost 30% year-to-date.
2025-10-14 07:39:53
Maryland State Retirement & Pension System has reduced its stake in Enovis Corporation ($ENOV) to a $521,000 position. This article details the institutional ownership of Enovis, highlighting significant increases by other hedge funds like Vanguard Group Inc., Invenomic Capital Management LP, and DAVENPORT & Co LLC. It also includes information on insider transactions, recent stock performance, and analyst ratings for Enovis.
2025-10-13 13:00:00
Enovis Corporation (NYSE: ENOV) has sold its Dr. Comfort diabetic shoe business to Promus Equity Partners for up to $60 million, comprising an upfront payment of $45 million and up to $15 million in contingent payments. This strategic divestiture allows Enovis to focus on its core Prevention & Recovery segment, aiming to streamline operations, expand margins, and reduce debt. Promus Equity Partners expressed enthusiasm for building on Dr. Comfort's legacy in serving clinicians, partners, and patients.
